Post-COVID-19 pulmonary fibrosis (PCPF) is a long-term complication that appears in some COVID-19 survivors. However, there are currently limited options for treating PCPF patients. To address this problem, we investigated COVID-19 patients’ transcriptome at single-cell resolution and combined biological network analyses to repurpose the drugs treating PCPF. We revealed a novel gene signature of PCPF. The signature is functionally associated with the viral infection and lung fibrosis. Further, the signature has good performance in diagnosing and assessing pulmonary fibrosis. Next, we applied a network-based drug repurposing method to explore novel treatments for PCPF. By quantifying the proximity between the drug targets and the signature in the interactome, we identified several potential candidates and provided a drug list ranked by their proximity. Taken together, we revealed a novel gene expression signature as a theragnostic biomarker for PCPF by integrating different computational approaches. Moreover, we showed that network-based proximity could be used as a framework to repurpose drugs for PCPF.
16 September 2025 in Open Forum Infectious Diseases
Background: Open-access data challenges can accelerate innovation in artificial intelligence–based tools. In the Cough Diagnostic Algorithm for Tuberculosis (CODA TB) DREAM Challenge, we developed and independently validated cough sound–based artificial intelligence algorithms for tuberculosis screening. Methods: We included data from 2143 adults with ≥2 weeks of cough from outpatient clinics in India, Madagascar, the Philippines, South Africa, Tanzania, Uganda, and Vietnam. A standard tuberculosis evaluation was completed, and ≥3 solicited coughs were recorded using a smartphone. We invited teams to develop models using training data to classify microbiologically confirmed tuberculosis disease using (1) cough sound features only and/or (2) cough sound features with routinely available clinical data. After 4 months, they submitted the algorithms for independent test set validation. Models were ranked by area under the receiver operating characteristic curve (AUROC) and partial AUROC (pAUROC) to achieve at least 80% sensitivity and 60% specificity. Results: Eleven cough models and 6 cough-plus-clinical models were submitted. AUROCs for cough models ranged from 0.69 to 0.74, and the highest performing model achieved 55.5% specificity (95% confidence interval, 47.7%–64.2%) at 80% sensitivity. The addition of clinical data improved AUROCs (range, 0.78–0.83); 5 of the 6 models reached the target pAUROC, and the highest performing model had 73.8% specificity (95% confidence interval, 60.8%–80.0%) at 80% sensitivity. The AUROC varied by country and was higher among male and human immunodeficiency virus–negative individuals. Conclusions: In a short period, an open-access data challenge facilitated the development of new cough-based tuberculosis algorithms and demonstrated potential as a tuberculosis screening tool.